Pfizer pays $620m for Aventis drug

Pfizer agreed to pay $620 million to acquire rights to Aventis’s Campto cancer drug in a transaction to gain antitrust approval for Aventis’s takeover by Sanofi-Synthelabo.

Pfizer already markets Campto in the US.

Aventis, which had Campto sales of €264m last year, sells the drug mainly in Europe, Asia and Africa under license from Yakult Honsha.